Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Jun 23, 2022
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
Jun 21, 2022
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Jun 16, 2022
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 10, 2022
EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting
May 17, 2022
EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com

MEDIA RELATIONS CONTACT
Amy Phillips
p. 412.327.9499
e. aphillips@greenroompr.com